drugset / Trial / NCT05821192
Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.
Unknown
34 enrolled
Ou Bai, MD/PHD
China-Japan Union Hospital, Jilin University · collabSecond Hospital of Jilin University · collab
NaSingle-groupOpen-labelTreatment
Summary
A multi-center, prospective clinical study to evaluate the efficacy and safety of R-GDP plus PD-1 monoclonal antibody in the treatment of refractory or relapsed peripheral T cell lymphoma not otherwise specified and Angioimmunoblastic T-cell lymphoma, which has previously shown promising efficacy.
Timeline
- Start
- 2023-03-23
- Primary completion
- 2023-04-18
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Background | Dexamethasone | Small molecule | 40 mg | Intravenous |
| Background | Gemcitabine | Small molecule | 1 g | Intravenous |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |